1665-5044

1665-5044

S1665-50442019000100003

10.24875/rmn.m19000018

México

México

00 02 2019

00 02 2019

20 1 3 13

1

2015 22 3 3

464-71

2

2017 78 3-4 3-4

128-36

3

2016 22

1064-85

4

2017 2017

5

2017 69

1409-16

6

2017 132

453-74

7

2016 33

S9-12

8

2013 69 6 6

321-4

9

1995 10 1 1

28-36

10

1995 58 6 6

681-7

11

Expert Consensus Group for Use of Apomorphine in Parkinson's Disease

2015 21 9 9

1023-30

12

2015 38 3 3

89-103

13

2016 6 4 4

787-92

14

1997 3 4 4

191-3

15

2013 8 1 1

63-8

16

2010 25 15 15

2649-53

17

2018 34 1 1

25-39

18

2013 13 12 12

1343-53

19

2016 27

35-40

20

2014 174 12 12

1930-3

21

1998 65 5 5

709-16

22

2016 33 Suppl 1 Suppl 1

S42-8

23

2017 7 4 4

603-17

24

1988 1 8582 8582

403-6

25

1988 2

1260

26

2018 17 9 9

749-59

27

2008 23 8 8

1130-6

28

2017 264 5 5

946-54

29

2016 33 Suppl 1 Suppl 1

S28-35

30

2013 19 12 12

1073-8

31

2004 9 9

291-6

32

2017 42 2 2

83-7

33

1986 20 2 2

262-5

34

1988 23 6 6

589-95

35

2014 78 1 1

94-105

36

2016 29

17-23

37

2012 19

1079-85

38

2013 260

105-14

39

French DUODOPA Study Group

2009 24 7 7

993-1000

40

2001 16 2 2

197-201

41

2015 21 7 7

742-8

42

2018 67 5 5

192-3

43

2016 6 3 3

187-202

44

2017 5 1 1

60-8

45

2012 6

37-50

46

2015 30 4 4

598-99

47

2017 8

44-53

48

LCIG Horizon Study Group

2014 13 2 2

141-9

49

Italian levodopa carbidopa intestinal gel working group

2017 38

90-2

50

2005 64 2 2

216-23

51

2015 30 4 4

500-9

52

2018 30 9 9

620

53

GLORIA study investigators and coordinators

2015 21 3 3

231-5

54

2018 20

1-11

55

National Steering Committees

2015 21 10 10

1133-44

56

2015 30 4 4

510-6

57

2016 63 12 12

529-36

58

2015 18 2 2

155-65

59

2017 20 11 11

1207-15